Eli Lilly (LLY): Gate Bioscience collaboration expansion for difficult-to-drug proteins
On Oct 5, Gate Bioscience announced an expanded collaboration with Lilly to target difficult-to-drug proteins. The stock initially showed no reaction but has since risen significantly, gaining +0.8σ on Oct 6 and +1.6σ on Oct 7, suggesting delayed positive market reception. No further specific catalysts are indicated.
Move beyond the market by session
In typical days (σ): the move of LLY beyond its usual link to QQQ. Darker bars are days with an event of the storyline; R marks a report window.
Chronology
Events of the storyline in the order they reached our feed, New York time. An event is one fact; its first headline and up to three other reports are shown.
Evening assessments
Every evening at 22:00 UTC while the storyline had news in the last three days. The model saw only the events that had arrived by then and the daily moves of the stock beyond the market.
15%+5 ▲ —
On Oct 5, Gate Bioscience announced an expanded collaboration with Lilly to target difficult-to-drug proteins. The stock initially showed no reaction but has since risen significantly, gaining +0.8σ on Oct 6 and +1.6σ on Oct 7, suggesting delayed positive market reception. No further specific catalysts are indicated.
Why: The collaboration expansion is fundamentally positive, but the next milestone or decision is not specified, so any new positive development would be a surprise. · size: medium · priced in: little
What the model was given · DeepSeek-V4-Flash, thinking high · a2
Company: LLY (Eli Lilly). Now: 2026-10-07 22:00 UTC (Wednesday). Storyline: Gate Bioscience collaboration expansion for difficult-to-drug proteins Chronology (UTC): - 10-05 12:04 Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins (+5 similar) Stock move beyond the market by session, in typical days (sigma): 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8, 10-07 +1.6
10% ▲ —
On October 5, Lilly expanded its collaboration with Gate Bioscience to target difficult-to-drug proteins. The stock showed a modest positive reaction on October 6, with a 0.8 sigma move. No further specific catalysts are pending.
Why: The collaboration expansion is a positive but incremental development for Lilly's pipeline, and the stock's modest move suggests it is partially priced in. · size: small: under one typical day · priced in: partly
What the model was given · DeepSeek-V4-Flash, thinking high · a2
Company: LLY (Eli Lilly). Now: 2026-10-06 22:00 UTC (Tuesday). Storyline: Gate Bioscience collaboration expansion for difficult-to-drug proteins Chronology (UTC): - 10-05 12:04 Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins (+5 similar) Stock move beyond the market by session, in typical days (sigma): 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8
10% • —
Eli Lilly expanded its collaboration with Gate Bioscience to target difficult-to-drug proteins, announced on October 5, 2026. The stock showed no significant reaction (flat vs. market), suggesting the news was already priced in or considered immaterial. No specific next catalyst is pending.
Why: The flat stock reaction indicates the collaboration expansion was anticipated or not seen as value-changing, and no further near-term catalysts are known. · size: small: under one typical day · priced in: mostly
What the model was given · DeepSeek-V4-Flash, thinking high · a2
Company: LLY (Eli Lilly). Now: 2026-10-05 22:00 UTC (Monday). Storyline: Gate Bioscience collaboration expansion for difficult-to-drug proteins Chronology (UTC): - 10-05 12:04 Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins (+5 similar) Stock move beyond the market by session, in typical days (sigma): 09-28 +0.1, 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0
How the model built the storyline
For each event the model was shown the company’s active storylines and chose: continue one, start a new one or treat the event as a one-off.
-
New storyline · Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
Question and answer · DeepSeek-V4-Flash, thinking high · s2
Company: LLY (Eli Lilly) New event (10-05 12:04 UTC): Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins also reported: Gate Bioscience expands Lilly drug discovery deal worth more than $870 million also reported: This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled Storylines: 1. Foundayo demonstrates cardiovascular safety in large type 2 diabetes trial first (09-30 22:02): Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study latest (10-02 22:46): Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study 2. Jaypirca FDA approval expansion for CLL/SLL first (10-02 19:07): Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL 3. Lilly takes over Milan facility in obesity battle with Novo first (10-02 08:20): Lilly Upstages Novo in Fresh Obesity Battle by Taking Over Milan 4. Lilly dispute with German health policy first (10-02 07:01): “My Trust Is Destroyed” Eli Lilly Boss Settles Accounts With German Health Policy - HB 5. Lilly exits Foghorn collaboration on cancer drug first (10-01 12:08): Foghorn plunges as Lilly exits collaboration latest (10-01 16:21): Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal 6. EloraTZP Phase 2 success in obesity and type 2 diabetes first (09-30 14:15): Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes latest (09-30 14:21): Experimental Lilly combination drug tops Zepbound in weight-loss trial 7. EBGLYSS Phase 3b success in hand and foot atopic dermatitis first (09-30 12:05): New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis 8. Retatrutide phase 3 results show substantial weight loss and A1C reduction first (09-29 22:02): Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes latest (09-30 00:12): ELI LILLY SAYS THE TRIPLE AGONIST ALSO REDUCED A1C IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES, WITH A BIOLOGICS LICENCE APPLICATION PLANNED FOR Q1 2027. 9. Foundayo shows superiority over oral semaglutide in diabetes analysis first (09-29 07:01): Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison latest (09-29 16:14): Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge 10. Zepbound shows greater weight loss than Wegovy in indirect comparison first (09-29 11:02): Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison 11. Novo Nordisk trial results show cardiovascular edge over Lilly's tirzepatide first (09-28 18:45): Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape? 12. Lilly U.S. manufacturing expansion first (09-21 21:40): Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 latest (09-28 14:40): He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket → {"story": 0, "title": "Gate Bioscience collaboration expansion for difficult-to-drug proteins"}